Clinical observations programme in SpA: Disease parameters, treatment options and practical management issues

Rheumatology International

Volumn 29, Issue 3, 2009, Pages 239-250

  Elewaut, Dirk ^a   Van Den Bosch, Filip ^a   Verbruggen, Gust ^a   De Keyser, Filip ^a   Cruyssen, Bert Vander ^a   Mielants, Herman ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Biologics; Inflammatory bowel disease; Psoriasis; Spondyloarthritides; TNF ; Tumour necrosis factor alpha; Uveitis

Indexed keywords

ADALIMUMAB; BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 1; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYLBUTAZONE; PLACEBO; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA;

ARTHRITIS; ARTICULAR CARTILAGE; AXIS; BALANITIS; BLADDER CARCINOMA; CATABOLISM; CROHN DISEASE; DIARRHEA; DIGESTIVE SYSTEM INFLAMMATION; DIGESTIVE SYSTEM ULCER; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE MODEL; DRUG DOSE TITRATION; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHEMA NODOSUM; EXTRACELLULAR MATRIX; GASTROINTESTINAL IRRITATION; GENETIC ANALYSIS; HOMEOSTASIS; HUMAN; INFLAMMATION; INJECTION SITE REACTION; IRIDOCYCLITIS; JOINT; JOINT DESTRUCTION; KERATODERMA BLENNORRHAGICA; LIGAMENT; LOWER RESPIRATORY TRACT INFECTION; OSTEOARTHRITIS; PRIORITY JOURNAL; PSORIASIS; PUSTULOSIS PALMOPLANTARIS; PYODERMA GANGRENOSUM; RETREATMENT; REVIEW; RHEUMATOID ARTHRITIS; SACROILIITIS; SKIN CARCINOMA; SPONDYLOARTHRITIDES; TENDINITIS; TENDON; TRANSITIONAL CELL CARCINOMA; TREATMENT WITHDRAWAL; ULCERATIVE COLITIS; URETHRITIS; UTERINE CERVICITIS; VAGINITIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; HUMANS; IRRITABLE BOWEL SYNDROME; OSTEOARTHRITIS; SEVERITY OF ILLNESS INDEX; SPONDYLARTHROPATHIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 57649176896     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-008-0714-5     Document Type: Review

References (84)

1. JM Moll I Haslock IF Macrae V Wright 1974 Associations between ankylosing spondylitis, psoriatic arthritis, Reiter's syndrome, the intestinal arthropathies, and Behcet's syndrome Medicine (Baltimore) 53 343 364 10.1097/00005792-197409000-00002
2. M Dougados S van der Linden R Juhlin B Huitfeldt B Amor A Calin The European Spondylarthropathy Study Group 1991 The European Spondyloarthroapthy Study Group preliminary criteria for the classification of spondyloarthropathy Arthritis Rheum 34 1218 1227 10.1002/art.1780341003
3. GS Boyer DW Templin A Bowler RC Lawrence SP Heyse DF Everett 1999 Spondyloarthropathy in the community: clinical syndromes and disease manifestations in Alaskan Eskimo populations J Rheumatol 26 1537 1544
4. JT Gran G Husby M Hordvik 1985 Prevalence of ankylosing spondylitis in males and females in a young middle-aged population of Tromsø, northern Norway Ann Rheum Dis 44 359 367
5. J Braun M Bollow G Remlinger U Eggens M Rudwaleit A Distler 1998 Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors Arthritis Rheum 41 58 67 10.1002/1529-0131(199801)41:1<58::AID-ART8>3.0. CO;2-G
6. A Saraux C Guedes J Allain V Devauchelle I Valls A Lamour 1999 Prevalence of rheumatoid arthritis and spondyloarthropathy in Brittany, France. Sociètè de Rhumatologie de l'Ouest J Rheumatol 26 2622 2627
7. A Calin S Brophy D Blake 1999 Impact of sex on inheritance of ankylosing spondylitis: a cohort study Lancet 354 1687 1690 10.1016/S0140-6736(99)03219-5
8. MA Khan 2002 Update on spondyloarthropathies Ann Intern Med 136 896 907
9. J Sieper M Rudwaleit MA Khan J Braun 2006 Concepts and epidemiology of spondyloarthritis Best Pract Clin Rheum 20 401 417 10.1016/j.berh.2006.02.001
10. M Rudwaleit A Metter J Listing J Sieper J Braun 2006 Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria Arthritis Rheum 54 569 578 10.1002/art.21619
11. MA Brown LG Kennedy AJ MacGregor C Darke E Duncan JL Shatford 1997 Susceptibility to ankylosing spondylitis in twins: the role of genes, HLA, and the environment Arthritis Rheum 40 1823 1828 10.1002/art.1780401015
12. SH Laval A Timms S Edwards L Bradbury S Brophy A Milicic 2001 Whole-genome screening in ankylosing spondylitis: evidence of non-MHC genetic-susceptibility loci Am J Hum Genet 68 918 926 10.1086/319509
13. R Said-Nahal C Miceli-Richard L Berthelot A Duché E Dernis-Labous G Le Blévec 2000 The familial form of spondyloarthropathy: a clinical study of 115 multiplex families. Groupe Français d'Etude Génétique des Spondyloarthropathies Arthritis Rheum 43 1356 1365 10.1002/1529-0131(200006)43:6<1356::AID-ANR20>3.0.CO;2-Y
14. J Martinez-Borra S Gonzalez A López-Vazquez MA Gelaz JB Armas U Kanga 2000 HLA-B27 alone rather than B27-related class I haplotypes contributes to ankylosing spondylitis susceptibility Hum Immunol 61 131 139 10.1016/S0198-8859(99)00145-7
15. RP Nair P Stuart T Henseler S Jenisch NV Chia E Westphal 2000 Localization of psoriasis-susceptibility locus PSORS1 to a 60-kb interval telomeric to HLA-C Am J Hum Genet 66 1833 1844 10.1086/302932
16. Y Ogura DK Bonen N Inohara DL Nicolae FF Chen R Ramos 2001 A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease Nature 411 603 606 10.1038/35079114
17. JP Hugot M Chamaillard H Zouali S Lesage JP Cèzard J Belaiche 2001 Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease Nature 411 599 603 10.1038/35079107
18. J Hampe A Cuthbert PJ Croucher MM Mirza S Mascheretti S Fisher 2001 Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations Lancet 357 1925 1928 10.1016/S0140-6736(00)05063- 7
19. D Laukens H Peeters D Marichal B Vander Cruyssen H Mielants D Elewaut 2005 CARD15 gene polymorphisms in patients with spondyloarthropathies identify a specific phenotype previously related to Crohn's disease Ann Rheum Dis 64 930 935 10.1136/ard.2004.028837
20. Wellcome Trust Case Control Consortium Australo-Anglo-American Spondylitis Consortium (TASC) PR Burton DG Clayton LR Cardon N Craddock P Deloukas A Duncanson DP Kwiatkowski MI McCarthy WH Ouwehand NJ Samani JA Todd P Donnelly JC Barrett D Davison D Easton DM Evans HT Leung JL Marchini AP Morris CC Spencer MD Tobin AP Attwood JP Boorman B Cant U Everson JM Hussey JD Jolley AS Knight K Koch E Meech S Nutland CV Prowse HE Stevens NC Taylor GR Walters NM Walker NA Watkins T Winzer RW Jones WL McArdle SM Ring DP Strachan M Pembrey G Breen D St Clair S Caesar K Gordon-Smith L Jones C Fraser EK Green D Grozeva ML Hamshere PA Holmans IR Jones G Kirov V Moskivina I Nikolov MC O'Donovan MJ Owen DA Collier A Elkin A Farmer R Williamson P McGuffin AH Young IN Ferrier SG Ball AJ Balmforth JH Barrett TD Bishop MM Iles A Maqbool N Yuldasheva AS Hall PS Braund RJ Dixon M Mangino S Stevens JR Thompson F Bredin M Tremelling M Parkes H Drummond CW Lees ER Nimmo J Satsangi SA Fisher A Forbes CM Lewis CM Onnie NJ Prescott J Sanderson CG Matthew J Barbour MK Mohiuddin CE Todhunter JC Mansfield T Ahmad FR Cummings DP Jewell J Webster MJ Brown MG Lathrop J Connell A Dominiczak CA Marcano B Burke R Dobson J Gungadoo KL Lee PB Munroe SJ Newhouse A Onipinla C Wallace M Xue M Caulfield M Farrall A Barton Biologics in RA Genetics and Genomics Study Syndicate (BRAGGS) Steering Committee IN Bruce H Donovan S Eyre PD Gilbert SL Hilder AM Hinks SL John C Potter AJ Silman DP Symmons W Thomson J Worthington DB Dunger B Widmer TM Frayling RM Freathy H Lango JR Perry BM Shields MN Weedon AT Hattersley GA Hitman M Walker KS Elliott CJ Groves CM Lindgren NW Rayner NJ Timpson E Zeggini M Newport G Sirugo E Lyons F Vannberg AV Hill LA Bradbury C Farrar JJ Pointon P Wordsworth MA Brown JA Franklyn JM Heward MJ Simmonds SC Gough S Seal Breast Cancer Susceptibility Collaboration (UK) MR Stratton N Rahman M Ban A Goris SJ Sawcer A Compston D Conway M Jallow M Newport G Sirugo KA Rockett SJ Bumpstead A Chaney K Downes MJ Ghori R Gwilliam SE Hunt M Inouye A Keniry E King R McGinnis S Potter R Ravindrarajah P Whittaker C Widden D Withers NJ Cardin D Davison T Ferreira J Pereira-Gale IB Hallgrimsdo'ttir BN Howie Z Su YY Teo D Vukcevic D Bentley MA Brown A Compston M Farrall AS Hall AT Hattersley AV Hill M Parkes M Pembrey MR Stratton SL Mitchell PR Newby OJ Brand J Carr-Smith SH Pearce R McGinnis A Keniry P Deloukas JD Reveille X Zhou AM Sims A Dowling J Taylor T Doan JC Davis L Savage MM Ward TL Learch MH Weisman M Brown 2007 Association scan of 14, 500 nonsynonymous SNPs in four diseases identifies autoimmunity variants Nat Genet 39 1329 1337
21. R Mapstone JD Woodrow 1975 HL-A 27 and acute anterior uveitis Br J Opthal 59 270 275 10.1136/bjo.59.5.270
22. JT Rosenbaum 1989 Characterization of uveitis associated with spondyloarthritis J Rheumatol 16 792 796
23. A Rothova MS van Veenedall A Linssen E Glasius A Kijlstra PT de Jong 1987 Clinical features of acute anterior uveitis Am J Ophthalmol 103 137 145
24. JL Lyons JT Rosenbaum 1997 Uveitis associated with inflammatory bowel disease compared with uveitis associated with spondyloarthropathy Arch Ophthalmol 115 61 64
25. ES Paiva DC Macaluso A Edwards JT Rosenbaum 2000 Characterisation of uveitis in patients with psoriatic arthritis Ann Rheum Dis 59 67 70 10.1136/ard.59.1.67
26. F Manguso M Sanges T Staiano S Gargiulo P Nastro D Gargano 2004 Cigarette smoking and appendectomy are risk factors for extraintestinal manifestations in ulcerative colitis Am J Gastroenterol 99 327 334 10.1111/j.1572-0241.2004. 04039.x
27. JC Jacobs WE Berdon AD Johnston 1982 HLA-B27-associated spondyloarthritis and enthesopathy in childhood: clinical, pathologic, and radiographic observations in 58 patients J Pediatr 100 521 528 10.1016/S0022-3476(82)80746-4
28. D Baeten E Kruithof F Van den Bosch N Van den Bossche A Herssens H Mielants 2003 Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? Ann Rheum Dis 62 829 834 10.1136/ard.62.9.829
29. N Turkcapar M Toruner I Soykan OT Aydintug H Cetinkaya N Duzgun 2006 The prevalence of extraintestinal manifestations and HLA association in patients with inflammatory bowel disease Rheumatol Int 26 663 668 10.1007/s00296-005- 0044-9
30. P Demetter D Baeten F De Keyser M De Vos N Van Damme G Verbruggen 2000 Subclinical gut inflammation in spondyloarthropathy patients is associated with upregulation of the E-cadherin/catenin complex Ann Rheum Dis 59 211 216 10.1136/ard.59.3.211
31. D Kontoyiannis M Pasparakis TT Pizarro F Cominelli G Kollias 1999 Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies Immunity 10 387 398 10.1016/S1074-7613(00)80038-2
32. JD Taurog JA Richardson JT Croft WA Simmons M Zhou JL Fernandez-Sueiro 1994 The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats J Exp Med 180 2359 2364 10.1084/jem.180.6. 2359
33. JF Hyla WA Franck JS Davis 1976 Lack of association of HLA B27 with radiographic sacroiliitis in inflammatory bowel disease J Rheumatol 3 196 200
34. S Steer H Jones J Hibbert E Kondeatis R Vaughan J Sanderson 2003 Low back pain, sacroiliitis, and the relationship with HLA-B27 in Crohn's disease J Rheumatol 30 518 522
35. D Elewaut JA DiDonato JM Kim F Truong L Eckmann MF Kagnoff 1999 NF-κB is a central regulator of the intestinal epithelial cell innate immune response induced by infection with enteroinvasive bacteria J Immunol 163 1457 1466
36. K De Vlam H Mielants C Cuvelier F De Keyser EM Veys M De Vos 2000 Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association J Rheumatol 27 2860 2865
37. H Mielants EM Veys C Cuvelier M De Vos S Goemaere L De Clercq 1995 The evolution of spondyloarthropathies in relation to gut histology. II. Histological aspects J Rheumatol 22 2273 2278
38. H Mielants EM Veys C Cuvelier M De Vos S Goemaere L De Clercq 1995 The evolution of spondyloarthropathies in relation to gut histology. III. Relation between gut and joint J Rheumatol 22 2279 2284
39. G Verbruggen 2006 Chondroprotective drugs in degenerative joint diseases Rheumatology (Oxford) 45 129 138 10.1093/rheumatology/kei171
40. J Wang D Elewaut EM Veys G Verbruggen 2003 Insulin-like growth factor 1-induced interleukin-1 receptor II overrides the activity of interleukin-1 and controls the homeostasis of the extracellular matrix of cartilage Arthritis Rheum 48 1281 1291 10.1002/art.11061
41. J Wang P Verdonk D Elewaut EM Veys G Verbruggen 2003 Homeostasis of the extracellular matrix of normal and osteoarthritis human articular cartilage chondrocytes in vitro Osteoarthritis Cartilage 11 801 809 10.1016/S1063-4584(03) 00168-7
42. V Moos S Fickert B Müller U Weber J Sieper 1999 Immunohistological analysis of cytokine expression in human osteoarthritic and healthy cartilage J Rheumatol 26 870 879
43. DM Butler RN Maini M Feldmann FM Brennan 1995 Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-alpha antibody with interleukin-1 receptor antagonist Eur Cytokine Netw 6 225 230
44. G Verbruggen EM Veys 1996 Numerical scoring systems for the anatomic evolution of osteoarthritis of the finger joints Arthritis Rheum 39 308 320 10.1002/art.1780390221
45. G Verbruggen R Wittoek S Groeneboer BV Cruyssen S Goemaere D Elewaut 2007 Osteochondral repair in synovial joints Curr Opin Rheumatol 19 265 271 10.1097/BOR.0b013e3280be58ff
46. JJ Anderson G Baron D van der Heijde DT Felson M Dougados 2001 Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis Arthritis Rheum 44 1876 1886 10.1002/1529-0131(200108) 44:8<1876::AID-ART326>3.0.CO;2-F
47. A van Tubergen D van der Heijde J Anderson R Landewé M Dougados J Braun 2003 Comparison of statistically derived ASAS improvement criteria for ankylosing spondylitis with clinically relevant improvement according to an expert panel Ann Rheum Dis 62 215 221 10.1136/ard.62.3.215
48. S Garrett T Jenkinson LG Kennedy H Whitelock P Gaisford A Calin 1994 A new approach to defining disease status in ankylosing spondylitis: the bath ankylosing spondylitis disease activity index J Rheumatol 21 2286 2291
49. A Spoorenberg S van der Heijde E de Klerk M Dougados K de Vlam H Mielants 1999 A comparative study of the usefulness of the bath ankylosing spondylitis functional index and the Dougados functional index in the assessment of ankylosing spondylitis J Rheumatol 26 961 965
50. D van der Heijde N Bellamy A Calin M Dougados MA Khan S van der Linden 1997 Preliminary core sets of endpoints in ankylosing spondylitis. Assessments in Ankylosing Spondylitis Working Group J Rheumatol 24 2225 2229
51. M Dougados B Dijkmans M Khan W Maksymowych S van der Linden J Brandt 2002 Conventional treatments for ankylosing spondylitis Ann Rheum Dis 61 suppl III iii40 iii50
52. J Zochling D van der Heijde R Burgos-Vargas E Collantes JC Davis B Dijkmans M Dougados P Géher RD Inman MA Khan TK Kvien M Leirisalo-Repo I Olivieri K Pavelka J Sieper G Stucki RD Sturrock S van der Linden D Wendling H Böhm BJ van Royen J Braun 'ASsessment in AS' international working group European League Against Rheumatism 2006 ASAS/EULAR recommendations for the management of ankylosing spondylitis Ann Rheum Dis 65 442 452 10.1136/ard.2005.041137
53. E Toussirot D Wendling 1998 Current guidelines for the drug treatment of ankylosing spondylitis Drugs 56 225 240 10.2165/00003495-199856020-00006
54. A Wanders D van der Heijde R Landewè JM Béhier A Calin I Olivieri 2005 Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial Arthritis Rheum 52 1756 1765 10.1002/art.21054
55. H Haibel M Rudwaleit J Listing J Sieper 2005 Open label trial of anakinra in active ankylosing spondylitis over 24 weeks Ann Rheum Dis 64 296 298 10.1136/ard.2004.023176
56. H Haibel M Ruwaleit J Braun J Sieper 2005 Six months open label trial of leflunomide in active ankylosing spondylitis Ann Rheum Dis 64 124 126 10.1136/ard.2003.019174
57. JC van Denderen M van der Paardt MT Nurmohamed YM de Ryck BA Dijkmans IE van der Horst-Bruinsma 2005 Double blind, randomised, placebo controlled study of leflunomide in the treatment of active ankylosing spondylitis Ann Rheum Dis 64 1761 1764 10.1136/ard.2005.036491
58. H Haibel HC Brandt IH Song A Brandt J Listing M Rudwaleit 2007 No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial Ann Rheum Dis 66 419 421 10.1136/ard.2006.054098
59. M Dougados S van der Linden M Leirisalo-Repo B Huitfeldt R Juhlin E Veys 1995 Sulfasalazine in the treatment of spondyloarthropathy. A randomized, multicenter, double-blind, placebo-controlled study Arthritis Rheum 38 618 627 10.1002/art.1780380507
60. DO Clegg DJ Reda MH Weismann WD Blackbrun JJ Cush GW Cannon 1996 Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study Arthritis Rheum 39 2004 2012 10.1002/art.1780391209
61. RF Willkens HJ Williams JR Ward MJ Egger JC Reading PJ Clements 1984 Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis Arthritis Rheum 27 376 381 10.1002/art.1780270403
62. JP Kaltwasser P Nash D Gladman CF Rosen F Behrens P Jones Treatment of Psoriatic Arthritis Study Group 2004 Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial Arthritis Rheum 50 1939 1950 10.1002/art.20253
63. M Bollow T Fischer H Reisshauer M Backhaus J Sieper B Hamm 2000 Quantitative analyses of sacroiliac biopsies in spondyloarthropathies: T cells and macrophages predominate in early and active sacroiliitis-cellularity correlates with the degree of enhancement detected by magnetic resonance imaging Ann Rheum Dis 59 135 140 10.1136/ard.59.2.135
64. L Laloux MC Voisin J Allain N Martin L Kerboull X Chevalier 2001 Immunohistological study of entheses in spondyloarthropathies: comparison in rheumatoid arthritis and osteoarthritis Ann Rheum Dis 60 316 321 10.1136/ard.60.4.316
65. J Braun M Bollow L Neure E Seipelt F Seyrekbasan H Herbst 1995 Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis Arthritis Rheum 38 499 505 10.1002/art.1780380407
66. F Van den Bosch E Kruithof D Baeten A Herssens F de Keyser H Mielants 2002 Randomized double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) versus placebo in active spondyloarthropathy Arthritis Rheum 46 755 765 10.1002/art.511
67. D van der Heijde B Dijkmans P Geusens J Sieper K DeWoody P Williamson J Braun Ankylosing Spondylitis Study for the Evaluation of the Recombinant Infliximab Therapy Study Group 2005 Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT) Arthritis Rheum 52 582 591 10.1002/art.20852
68. C Antoni GG Krueger K de Vlam C Birbara A Beutler C Guzzo B Zhou LT Dooley A Kavanaugh IMPACT 2 Investigators 2005 Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial Ann Rheum Dis 64 1150 1157 10.1136/ard.2004.032268
69. J Braun J Brandt J Listing A Zink R Alten G Burmester 2003 Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial Arthritis Rheum 48 2224 2233 10.1002/art.11104
70. J Braun X Baraliakos J Brandt J Listing A Zink R Alten 2005 Persistent clinical response to the anti-TNF-α antibody infliximab in patients with ankylosing spondylitis over 3 years Rheumatology (Oxford) 44 670 676 10.1093/rheumatology/keh584
71. J Braun X Baraliakos J Listing C Fritz R Alten G Burmester 2008 Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response Ann Rheum Dis 67 340 345 10.1136/ard.2007.075879
72. F Van den Bosch M Devinck E Kruithof G Verbruggen F De Keyser H Mielants 2005 5-year safety and efficacy follow-up in 107 spondyloarthropathy patients with continued long-term infliximab treatment Ann Rheum Dis 64 suppl III 330 10.1136/ard.2004.022111
73. F Van den Bosch E Kruithof M De Vos F De Keyser H Mielants 2000 Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms Lancet 356 1821 1822 10.1016/S0140-6736(00) 03239-6
74. H Marzo-Ortega D McGonagle P O'Connor P Emery 2003 Efficacy of etanercept for treatment of Crohn's related spondyloarthritis but not colitis Ann Rheum Dis 62 74 76 10.1136/ard.62.1.74
75. J Braun X Baraliakos J Listing J Davis D van der Heijde H Haibel 2007 Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents Arthritis Rheum 57 639 647 10.1002/art.22669
76. X Baraliakos J Listing J Brandt A Zink R Alten G Burmester 2005 Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab Arthritis Res Ther 7 R439 R444 10.1186/ar1693
77. PJ Mease AJ Kivitiz FX Burch EL Siegel SB Cohen P Ory 2004 Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression Arthritis Rheum 50 2264 2272 10.1002/art.20335
78. DM van der Heijde RDM Landewè P Ory D Vosse L Zhou W Tsuji 2006 Two-year etanercept therapy does not inhibit radiographic progression in patients with ankylosing spondylitis Ann Rheum Dis 65 suppl II 81 10.1136/ard.2005.037671
79. D van der Heijde R Landewè A Deodar D Baker J Han W Xu 2007 Radiographic progression in patients with ankylosing spondylititis after 2 years of treatment not inhibited with infliximab Ann Rheum Dis 66 suppl II 85
80. WG Dixon K Watson M Lunt KL Hyrich AJ Silman DP Symmons British Society for Rheumatology Biologics Register 2006 Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register Arthritis Rheum 54 2368 2376 10.1002/art.21978
81. L Carmona JJ Gòmez-Reino V Rodrìguez-Valverde D Montero E Pascual-Gòmez EM Mola BIOBADASER Group 2005 Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists Arthritis Rheum 52 1766 1772 10.1002/art.21043
82. J Keane S Gershon RP Wise E Mirabile-Levens J Kasznica WD Schwieterman 2001 Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent N Engl J Med 345 1098 1104 10.1056/NEJMoa011110
83. DE Furst J Cush S Kaufmann J Siegal R Kurth 2002 Preliminary guidelines for diagnosing and treating tuberculosis in patients with rheumatoid arthritis in immunosuppressive trials or being treated with biological agents Ann Rheum Dis 61 suppl 2 ii2 ii3 10.1136/ard.61.5.476
84. MA Gardam EC Keystone R Menzies S Manners E Skamene R Long 2003 Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management Lancet Infect Dis 3 148 155 10.1016/S1473-3099(03)00545- 0